Drug name - Aponvie

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
32MG/4.4ML (7.2MG/ML) EMULSION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in